INTRODUCTION
Age-related facial changes have been characterized by a loss of hyaluronic acid (HA) and subcutaneous volume.1 On account of its excellent tolerance and hydroscopic properties, HA is an ideal candidate to create volume in soft tissues like the skin.2 Given that natural HA in the skin has an extremely rapid turn-over rate, commercially available HAs have been stabilized by means of different manufacturing techniques, resulting in products that vary in formulation and degree of cross-linking.
Numerous dermal HA fillers were manufactured using the patented cohesive polydensified matrix (CPM™) technology. This technology relies on the dynamic double cross-linking of monophasic HA strands with 1,4-butanediol diglycidyl ether (BDDE), leading to a product with variable cross-linking densities within the gel, denser areas ensuring voluminizing effects, and less dense areas the matrix cohesivity. This ensures optimal spreading of the gel into surrounding tissues allowing larger spaces to be filled with denser gel parts and finer tissue spaces to retain low-density gel, resulting in one continuous network. All these features were demonstrated by our research team in several ultrasonography and histology studies,3-6 with recently published data further confirming our own results.7
The patented Vycross™ (Allergan, Inc, Irvine, CA) technology incorporates short-chain HA together with long-chain HA, with the aim to improve the cross-linking efficiency of HA. Including short-chain HA allows more cross-linkers to attach to HA chains at both ends, thereby resulting in a longer product duration than fillers with only long-chain HA. As of 2015, there were three different HA gel types available relying on this technology: Juvéderm Volbella®, Juvéderm Voluma®, and Juvéderm Volift®.
Juvéderm Volbella
This injectable gel used in combination with lidocain is the subject of this paper. According to the Patient Information Leaflet, the gel is indicated for the treatment of any fine lines and me-